Anticonvulsants
The mechanisms by which anticonvulsants damp excitation or raise inhibition, the pharmacology of phenytoin as the classic exam drug, the properties of the other major agents, the reasoning behind the sequence of drugs used in status epilepticus, and the interactions, toxicities and special situations that matter.
By the end of this page you should be able to
- Describe the four main molecular targets of anticonvulsant drugs with examples of each.
- Explain use-dependent sodium channel blockade and why it suppresses seizures without abolishing normal firing.
- Describe the pharmacokinetics of phenytoin, including zero-order behaviour, protein binding and interactions.
- Compare the other major agents by mechanism, kinetics and characteristic adverse effects.
- Explain the pharmacological reasoning behind escalating therapy in status epilepticus.
- Describe the important interactions, toxicities and considerations in pregnancy.
Mechanisms
A seizure is excitation outrunning inhibition in a population of neurones, with synchronous high-frequency firing that spreads. Every anticonvulsant either reduces excitation or increases inhibition, through one of four targets.
Voltage-gated sodium channels. Phenytoin, carbamazepine, lamotrigine and lacosamide bind the channel preferentially in its inactivated state and slow its recovery. Because a channel spends more time inactivated the faster it is cycling, the effect is use-dependent: it accumulates in rapidly firing neurones and barely affects normal traffic. This is the single most important pharmacological idea in the topic, and it also explains the cardiac effects of these drugs, since cardiac myocytes use the same channel family.
GABA-A mediated inhibition. Benzodiazepines (increasing the frequency of channel opening) and barbiturates (increasing the duration, and at high concentration opening the channel directly) raise chloride conductance and make neurones harder to excite. This is the quickest way to stop a seizure, at the price of sedation and respiratory depression.
Presynaptic release. Levetiracetam binds the synaptic vesicle protein SV2A and reduces excitatory transmitter release; the gabapentinoids bind the alpha-2-delta subunit of presynaptic voltage-gated calcium channels with the same net effect.
Thalamic T-type calcium channels and glutamate receptors. Ethosuximide suppresses the thalamocortical oscillation that generates absence seizures, which is why it works for that seizure type and not others. Valproate and topiramate are broad-spectrum because they act at several of these targets at once.
Phenytoin
- Mechanism: use-dependent sodium channel blockade. It is effective in focal and generalised tonic-clonic seizures and may worsen absence and myoclonic seizures.
- Zero-order kinetics: the enzymes that metabolise it saturate within the therapeutic range, so above that point clearance is fixed and the concentration rises disproportionately with small increases in exposure. This is why it has a narrow therapeutic index, why monitoring is used, and why the relationship between amount given and concentration is not linear.
- Protein binding: about 90 per cent bound to albumin, and only the free fraction is active. In hypoalbuminaemia, uraemia, pregnancy and with displacing drugs, the total measured concentration underestimates the free concentration, so a patient can be toxic with a "normal" level. Either measure the free concentration or correct for albumin.
- Interactions: it is a potent inducer of several cytochrome P450 enzymes, so it lowers the concentrations of warfarin (initially raised by displacement), oral contraceptives, other anticonvulsants, some antimicrobials and many other drugs. It is itself inhibited by valproate, isoniazid, fluconazole and others.
- Dose-related toxicity follows a recognisable sequence as the concentration rises: nystagmus, then ataxia and dysarthria, then confusion and sedation, and at high concentrations paradoxical seizures. Cardiovascular toxicity (hypotension, bradycardia, widened QRS and arrhythmia) is largely a feature of rapid intravenous administration, caused both by the sodium channel effect and by the propylene glycol diluent, which is why the rate of administration is limited and why fosphenytoin, a water-soluble prodrug, is better tolerated.
- Idiosyncratic and chronic effects: rash including Stevens-Johnson syndrome and toxic epidermal necrolysis (associated with the HLA-B*1502 allele in some populations), hypersensitivity syndrome with fever, rash and hepatitis, gingival hyperplasia, hirsutism, coarse facies, cerebellar atrophy, megaloblastic anaemia from impaired folate metabolism, osteomalacia from vitamin D metabolism, and purple glove syndrome after extravasation.
The other agents
- Benzodiazepines (midazolam, diazepam, lorazepam, clonazepam): fast, reliable seizure termination through GABA-A. They differ in kinetics rather than mechanism: diazepam is highly lipid soluble so it enters and leaves the brain quickly, while lorazepam has a longer duration of effect because of slower receptor dissociation despite a shorter half-life. Adverse effects are sedation, respiratory depression, hypotension and tolerance.
- Valproate: multiple actions (sodium channels, raised GABA, T-type calcium channels), broad-spectrum. It is an enzyme inhibitor, so it raises the concentrations of other drugs, and it displaces phenytoin. Adverse effects: hepatotoxicity, hyperammonaemic encephalopathy, pancreatitis, thrombocytopenia and platelet dysfunction, weight gain, tremor, hair loss, and significant teratogenicity with neural tube defects and neurodevelopmental harm, so it is avoided wherever possible in those who may become pregnant.
- Levetiracetam: SV2A binding, broad-spectrum, no hepatic metabolism and no important interactions, mainly renally cleared (so the amount is reduced in renal impairment). Adverse effects are behavioural: irritability, agitation and mood change. These properties are why it has become a common second-line agent.
- Carbamazepine: sodium channel blocker, also used in trigeminal neuralgia and as a mood stabiliser. It induces its own metabolism (autoinduction), causes hyponatraemia through a vasopressin-like effect, and has an epoxide metabolite that accumulates with valproate. Adverse effects include rash, marrow suppression, and the same rash and HLA associations as phenytoin. In overdose it behaves like a tricyclic, with anticholinergic features and sodium channel blockade.
- Lamotrigine: sodium channel blocker, well tolerated and broad-spectrum, but needs slow introduction because rapid escalation causes severe rash; valproate inhibits its metabolism and markedly prolongs it.
- Phenobarbitone: a barbiturate with a very long half-life and potent enzyme induction; still used in neonatal and refractory seizures, with marked sedation and respiratory depression.
- Topiramate (multiple mechanisms, weight loss, paraesthesia, metabolic acidosis from carbonic anhydrase inhibition, renal stones) and sodium valproate alternatives such as lacosamide (slow inactivation of sodium channels, few interactions, PR prolongation) complete the common list.
Reasoning through status epilepticus
The pharmacology explains the sequence, and that is what a viva asks for.
First comes a benzodiazepine, because GABA-A enhancement is the fastest and most reliable way to terminate seizure activity, and because the route can be adapted to access (intravenous, intramuscular, buccal or intranasal all work, which matters when there is no line). The reasons for failure are also pharmacological: an inadequate quantity, and the progressive internalisation of GABA-A receptors as a seizure continues, which makes benzodiazepines less effective the longer the seizure has lasted. This is the argument for prompt, adequate treatment rather than repeated small increments.
Second comes a non-benzodiazepine agent with a different mechanism: levetiracetam, a sodium channel agent such as phenytoin or fosphenytoin, or valproate. Trial evidence shows little difference in efficacy between them, so the choice rests on the patient: interactions, renal and hepatic function, cardiac conduction, pregnancy and what the patient already takes.
Third, if seizures continue, is anaesthesia with an agent that acts on GABA-A or NMDA pathways, with intubation and ventilation, because at this point the aim is to abolish electrical activity and protect the brain and airway.
Throughout, the reversible precipitants are treated in parallel, since no anticonvulsant will work against an ongoing cause: hypoglycaemia, hyponatraemia, hypocalcaemia and hypomagnesaemia, hypoxia, eclampsia (where magnesium, not a standard anticonvulsant, is the specific treatment), isoniazid toxicity (where pyridoxine is the antidote because the seizures result from functional pyridoxine deficiency), alcohol withdrawal, drug toxicity, meningitis, intracranial bleeding and raised intracranial pressure. For quantities, rates and regimens, follow your local status epilepticus protocol and the Australian Medicines Handbook.
Making the answer flow
- Open with the four mechanisms, then place each drug; it turns a list of agents into a short framework.
- Explain use-dependence properly: inactivated state binding, slowed recovery, selectivity for rapidly firing neurones.
- For phenytoin, cover zero-order kinetics, protein binding and the difference between rate-related and dose-related toxicity.
- In status epilepticus, justify each step pharmacologically and mention receptor internalisation as the reason for acting early.
Where marks are lost
- Saying phenytoin follows first-order kinetics in the therapeutic range.
- Interpreting a total phenytoin concentration in hypoalbuminaemia without correction.
- Attributing all phenytoin cardiovascular toxicity to the drug and forgetting the rate and the diluent.
- Forgetting that valproate is an enzyme inhibitor while phenytoin and carbamazepine are inducers.
- Treating eclamptic or isoniazid-related seizures with standard anticonvulsants alone instead of the specific agent.
Where this meets intensive care
- Phenytoin's zero-order kinetics in the therapeutic range and high protein binding make levels hard to predict in critical illness; measure free levels when albumin is low.
- Benzodiazepine resistance develops during prolonged status epilepticus as GABA-A receptors are internalised and NMDA receptors are upregulated, which is why second-line agents with other mechanisms follow quickly.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
What are the main mechanisms of anticonvulsant drugs?
Show answer
- Use-dependent sodium channel blockade: phenytoin, carbamazepine, lamotrigine, lacosamide.
- Enhancement of GABA-A inhibition: benzodiazepines, barbiturates, propofol.
- Reduced excitatory transmitter release: levetiracetam at SV2A, gabapentinoids at alpha-2-delta.
- T-type calcium channel and glutamate effects: ethosuximide, topiramate; valproate acts at several targets.
- 2.
Explain use-dependent sodium channel blockade.
Show answer
- The drug binds the channel in its inactivated state and slows recovery to the resting state.
- Rapidly firing neurones spend more time inactivated, so blockade accumulates where firing is abnormal.
- Normal low-frequency firing is relatively spared, which gives seizure selectivity.
- The same mechanism in cardiac myocytes explains QRS widening and arrhythmia in toxicity.
- 3.
Describe the pharmacokinetics of phenytoin.
Show answer
- Saturable, zero-order metabolism within the therapeutic range, so concentration rises disproportionately.
- About 90 per cent albumin bound; only free drug is active, so hypoalbuminaemia and uraemia raise the free fraction.
- Hepatic metabolism with potent enzyme induction; many interactions in both directions.
- Narrow therapeutic index, so therapeutic monitoring with attention to albumin or free levels.
- 4.
What are the features of phenytoin toxicity?
Show answer
- Concentration-related: nystagmus, then ataxia and dysarthria, then confusion and coma, and paradoxical seizures at high levels.
- Rate-related on intravenous administration: hypotension, bradycardia, QRS widening and arrhythmia, partly from the propylene glycol diluent.
- Idiosyncratic: rash including Stevens-Johnson syndrome, hypersensitivity syndrome, hepatitis, marrow suppression.
- Chronic: gingival hyperplasia, hirsutism, coarse facies, cerebellar atrophy, folate and vitamin D effects.
- 5.
Compare levetiracetam and valproate.
Show answer
- Levetiracetam: SV2A binding, renally cleared, no significant interactions, behavioural adverse effects.
- Valproate: multiple mechanisms, hepatic metabolism, enzyme inhibitor, broad-spectrum.
- Valproate adverse effects: hepatotoxicity, hyperammonaemic encephalopathy, pancreatitis, thrombocytopenia, weight gain, teratogenicity.
- Choice depends on interactions, organ function, pregnancy potential and seizure type.
- 6.
Why do benzodiazepines become less effective the longer a seizure lasts?
Show answer
- Prolonged seizure activity causes internalisation and reduced surface expression of GABA-A receptors.
- Fewer available receptors means less effect from a positive allosteric modulator.
- NMDA receptor expression simultaneously increases, raising excitability.
- Clinical consequence: treat early with an adequate quantity rather than repeated small increments, and escalate promptly.
- 7.
Talk me through the pharmacological reasoning in status epilepticus.
Show answer
- Benzodiazepine first for rapid GABA-A enhancement, by whatever route is available.
- Then a second-line agent with a different mechanism: levetiracetam, phenytoin or fosphenytoin, or valproate; choice by patient factors.
- Then anaesthesia with intubation if seizures persist, to abolish activity and protect the airway and brain.
- Treat reversible precipitants in parallel: glucose, sodium, calcium, magnesium, oxygenation, eclampsia with magnesium, isoniazid toxicity with pyridoxine, alcohol withdrawal, infection and intracranial causes.
- 8.
Which anticonvulsant interactions matter most, and why?
Show answer
- Phenytoin, carbamazepine and phenobarbitone are inducers: they lower concentrations of warfarin, contraceptives, antiretrovirals and other anticonvulsants.
- Valproate is an inhibitor: it raises lamotrigine and the carbamazepine epoxide metabolite and displaces phenytoin.
- Protein binding displacement raises the free fraction of phenytoin even when total levels look unchanged.
- Carbamazepine autoinduction means its own concentration falls in the first weeks of treatment.
Practise this week
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 15 in the other subjects
- Physiology: Acid-base balance and potassium
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.